Novo Nordisk, the Danish pharmaceutical giant best known for developing the weight-loss injection Wegovy, has announced a landmark deal to acquire US-listed biotech Akero Therapeutics for up to $5.2 billion.
Novo Nordisk, the Danish pharmaceutical giant best known for developing the weight-loss injection Wegovy, has announced a landmark deal to acquire US-listed biotech Akero Therapeutics for up to $5.2 billion.
GSK, one of the UK’s leading pharmaceutical companies, has committed up to $2 billion to acquire a promising new liver disease drug from Boston Pharmaceuticals. The latest acquisition aims to






